The world's first death from secondary coronary pneumonia

(2020/10/16) Otsuka Guadecitabine and two more late-stage blood tumor trials failed; (Click on the title to get the original text) (Medicine 1st time) consecutive defeats! The failure of two more late-stage blood tumor trials in Otsuka Guadecitabine was followed by the failure of two phase III blood tumor clinical trials in Guadecitabine (SGI-110), a subsidiary of Otsuka Pharmaceuticals of Japan.
, the drug failed to achieve positive results in three late-stage trials.
: The failure of three Phase III trials is undoubtedly a major blow to Otsuka Pharmaceuticals.
the development course of mass procurement and the reform of drug prices in the first three batches of strip procurement have always been an important part of China's medical and health system reform.
Before the reform and opening-up, the government unified control, the use of the purchase and sale of drug cost increases, until 1978, the government gradually opened up drug prices, the drug market presents a liberalized competitive landscape, at this time most pharmaceutical enterprises belong to free pricing, market order chaos; The Interim Measures for drug Price Management were issued, and the government resumed macro-control over drug prices, and then to control the proportion of drugs-based medical cost structure reform, centralized procurement, is not only looking for a reasonable way to reduce drug prices, but still failed to control the problem of high drug prices, and volume procurement is the upgrading of the multi-year drug price management model.
: Medicare, base drugs are still the core category.
the world's first case of secondary neo-coronary pneumonia, antibodies are disappearing or are viruses evolving? Dutch researchers report that the 89-year-old woman has Fahrenheit globulinemia, a rare blood lymphoma that has been undergoing chemotherapy.
her first infection with the new coronavirus, she developed fever, severe cough and other symptoms, and was cured and discharged after five days in hospital.
: The outbreak of new crown pneumonia in the Netherlands continues to intensify.
( U.S. Traditional Chinese Medicine Source ) Redsivir's ineffectiveness in reducing neo crown mortality Today WHO released some information about the largest new crown Phase III clinical Solidarity trial to date, with the exception of the old drug symethon and three other therapies (Redsivir, hydroxychloroquine, Lopinavir/interferon combination) that did not show a reduction in mortality and intestor risk in patients with new crowns.
the trial recruited a total of 11,266 new patients who needed to be hospitalized, and the Redsiway group had 2,750 people who shared the drug for 10 days.
not only did not reduce mortality, but the trial also found that the drug reduced hospital stay, but that was not the main endpoint of the trial.
: Gilead's performance throughout the process was not flattering.